The Treatment of Refractory Vitiligo With Autologous Cultured Epithelium Grafting : A Real-World Retrospective Cohort Study
© The Author(s) 2024. Published by Oxford University Press..
BACKGROUND: Surgical intervention is the main therapy for refractory vitiligo. We developed a modified autologous cultured epithelial grafting (ACEG) technique for vitiligo treatment. Between January 2015 and June 2019, a total of 726 patients with vitiligo underwent ACEG in China, with patient characteristics and clinical factors being meticulously documented. Using a generalized linear mixed model, we were able to assess the association between these characteristics and the repigmentation rate.
RESULTS: ACEG demonstrated a total efficacy rate of 82.81% (1754/2118) in treating 726 patients, with a higher repigmentation rate of 64.87% compared to conventional surgery at 52.69%. Notably, ACEG showed a better response in treating segmental vitiligo, lesions on lower limbs, age ≤ 18, and stable period > 3 years. A keratinocyte:melanocyte ratio below 25 was found to be advantageous too. Single-cell RNA sequencing analysis revealed an increase in melanocyte count and 2 subclusters of keratinocytes after ACEG, which remained higher in repigmented sites even after 1 year.
CONCLUSIONS: ACEG is a promising therapy for refractory vitiligo. Patient age, clinical type, lesion site, and stability before surgery influence repigmentation in ACEG. The mechanism of repigmentation after ACEG treatment is likely not confined to the restoration of melanocyte populations. It may also involve an increase in the number of keratinocytes that support melanocyte function within the affected area. These keratinocytes may aid the post-transplant survival and function of melanocytes by secreting cytokines and extracellular matrix components.
TRIAL REGISTRATION: registered with Chictr.org.cn (ChiCTR2100051405).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Stem cells translational medicine - (2024) vom: 21. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Jian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/stcltm/szae009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370028589 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370028589 | ||
| 003 | DE-627 | ||
| 005 | 20240323001823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/stcltm/szae009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM370028589 | ||
| 035 | |a (NLM)38513284 | ||
| 035 | |a (PII)szae009 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Jian |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Treatment of Refractory Vitiligo With Autologous Cultured Epithelium Grafting |b A Real-World Retrospective Cohort Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press. | ||
| 520 | |a BACKGROUND: Surgical intervention is the main therapy for refractory vitiligo. We developed a modified autologous cultured epithelial grafting (ACEG) technique for vitiligo treatment. Between January 2015 and June 2019, a total of 726 patients with vitiligo underwent ACEG in China, with patient characteristics and clinical factors being meticulously documented. Using a generalized linear mixed model, we were able to assess the association between these characteristics and the repigmentation rate | ||
| 520 | |a RESULTS: ACEG demonstrated a total efficacy rate of 82.81% (1754/2118) in treating 726 patients, with a higher repigmentation rate of 64.87% compared to conventional surgery at 52.69%. Notably, ACEG showed a better response in treating segmental vitiligo, lesions on lower limbs, age ≤ 18, and stable period > 3 years. A keratinocyte:melanocyte ratio below 25 was found to be advantageous too. Single-cell RNA sequencing analysis revealed an increase in melanocyte count and 2 subclusters of keratinocytes after ACEG, which remained higher in repigmented sites even after 1 year | ||
| 520 | |a CONCLUSIONS: ACEG is a promising therapy for refractory vitiligo. Patient age, clinical type, lesion site, and stability before surgery influence repigmentation in ACEG. The mechanism of repigmentation after ACEG treatment is likely not confined to the restoration of melanocyte populations. It may also involve an increase in the number of keratinocytes that support melanocyte function within the affected area. These keratinocytes may aid the post-transplant survival and function of melanocytes by secreting cytokines and extracellular matrix components | ||
| 520 | |a TRIAL REGISTRATION: registered with Chictr.org.cn (ChiCTR2100051405) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a keratinocyte | |
| 650 | 4 | |a melanocyte | |
| 650 | 4 | |a single-cell sequencing | |
| 650 | 4 | |a transplantation | |
| 650 | 4 | |a vitiligo | |
| 700 | 1 | |a Zeng, Xuanhao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shujun |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Luyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Minzi |e verfasserin |4 aut | |
| 700 | 1 | |a Lian, Weiling |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jinqi |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Haozhen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yating |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Jiayi |e verfasserin |4 aut | |
| 700 | 1 | |a Uyama, Taro |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Fuyue |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jinfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jinhua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cells translational medicine |d 2012 |g (2024) vom: 21. März |w (DE-627)NLM217286267 |x 2157-6580 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/stcltm/szae009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 | ||